CGEN Compugen Ltd.

BUSINESS SUMMARY

Compugen is an Israel-based clinical-stage biotechnology company specializing in computational target discovery for cancer immunotherapy. The company was founded as a bioinformatics platform in 1993 and has spent decades building an in-house AI/ML-driven approach to identifying novel drug targets — particularly immune checkpoints beyond PD-1/PD-L1.

The current pipeline is a mix of in-house clinical-stage assets (notably COM701 and COM902, which target PVRIG and TIGIT respectively) and partnership-derived programs with major pharma. Historically, Compugen's primary revenue stream has been upfront payments and milestones from licensing partnerships with companies including Bristol-Myers Squibb, AstraZeneca, and Gilead.

Revenue is lumpy by nature — milestone-driven income spikes when a partner advances a Compugen-discovered program through a clinical or regulatory checkpoint, and is near-zero in quarters without such events.

MARKET OPPORTUNITY

The cancer immunotherapy market is enormous and well-funded but increasingly competitive:

• TIGIT is the most-prosecuted post-PD-1 checkpoint; multiple Phase 3 readouts have disappointed (Roche's tiragolumab, Merck's vibostolimab) but the target itself is still considered viable in the right combinations
• PVRIG is a less-prosecuted target where Compugen has the most-advanced clinical asset (COM701)
• Computational-discovery-driven novel targets — Compugen's pipeline always includes earlier-stage assets coming out of the platform that haven't been disclosed publicly yet

Macro context: 161.1% YoY revenue growth is a milestone-spike, not a steady-state trajectory. Investors evaluating Compugen on revenue-multiple metrics fundamentally misunderstand the business model. The right framing is clinical-pipeline NPV plus near-term partnership-milestone optionality, not annualized revenue.

REVENUE QUALITY

The standard fundamental metrics are misleading for a clinical-stage biotech with a partnership-revenue model:

• Gross margin 87.3% — meaningless when revenue is milestone-driven; gross margin will be high or low purely as a function of which partnership triggers in a given quarter
• Operating margin 43.1% — same caveat; the operating-leverage shows in milestone-quarters and disappears in quiet quarters
• Cash $90.6M, debt $3M — much more important than the income statement; this is the operating-runway anchor
• Rule of 40 of 204 — mechanical artifact of milestone-revenue lumpiness; should not be benchmarked against software peers

What investors should actually track:

• Cash runway (~3 years at current burn) — the single most-watched metric in clinical-stage biotech
• Clinical-readout cadence for COM701, COM902, and partnered programs
• Partnership-pipeline news — new deals expand the platform's monetization, lost partnerships compress it

COMPETITIVE ADVANTAGE

The defensible asset is the computational-target-discovery platform plus the resulting target IP and clinical-stage pipeline:

• Platform durability — the same approach has produced multiple partnership-monetized targets over 15 years; that is a meaningful track record in computational drug discovery, where most platforms fail
• TIGIT and PVRIG IP — both targets have meaningful patent-and-data protection; even where larger pharma has competing programs, the foundational discovery-IP is Compugen's
• Partnership relationships with multiple top-20 pharma companies — these are slow to build and reflect platform-credibility

What it is not: a moat against vertically-integrated big-pharma immuno-oncology programs. Roche, Merck, BMS, AstraZeneca all have their own discovery operations and don't need Compugen's platform on the most strategic targets. Compugen's moat is in the second-tier targets where big-pharma needs partner-derived ideas.

GROWTH THESIS

Three things have to work:

1. In-house clinical assets advance. COM701 and COM902 reading out positive Phase 2 data would meaningfully derisk the in-house pipeline and reset the multi-year value framework.
2. New partnership deals close. Each new BMS-, AstraZeneca-, Gilead-class partnership is upfront cash plus future-milestone optionality; a multi-year drought in new deals would signal the platform is losing relevance.
3. TIGIT and PVRIG remain viable in the broader IO market. If sequential Phase 3 failures of TIGIT-class agents continue, the market may write off the entire mechanism, and Compugen's most-advanced asset class loses commercial optionality regardless of any individual trial result.

The 2.1% insider ownership is very low — the float is institutionally-owned, which means the stock can move sharply on individual analyst-revisions or biotech-fund-flow shifts.

KEY RISKS

Three specific risks:

1. TIGIT-class continued failure in Phase 3. Multiple high-profile failures (Roche tiragolumab in lung cancer, Merck vibostolimab) have already damaged the mechanism's perception. Another large-trial failure could write off the entire target class, and Compugen's COM902 commercial optionality with it.

2. Partnership-milestone schedule slips. The visible revenue trajectory depends heavily on partnership-milestone timing. If two or three expected milestones slip from 2026 into 2027-2028, near-term revenue collapses and the cash-runway narrative tightens, even though clinical progress may be on track.

3. Cash-runway exhaustion before in-house clinical readouts. ~3 years of runway sounds long but biotech timelines slip. If COM701 or COM902 clinical readouts move materially right, Compugen could face a dilutive financing in a depressed-biotech-tape environment, which destroys per-share economics.

VERDICT

The 89.7/100 score is the most-misleading high score in our entire universe — the fundamental metrics are mathematical artifacts of a milestone-revenue accounting model, not steady-state quality indicators. A clinical-stage biotech should not be evaluated by Rule of 40, P/S, and operating margin. The right framing is pipeline-NPV plus runway plus optionality.

For investors who understand clinical-stage biotech investing, can model partnership-driven revenue lumpiness, and can underwrite TIGIT/PVRIG as viable mechanisms, CGEN is a credible mid-tier IO biotech name with real platform credentials. For investors using fundamental-screening frameworks designed for operating businesses, the score will systematically mislead.

The single metric to watch next is COM701 Phase 2 readouts in 2026-2027. A clear positive signal in any solid-tumor cohort moves the company from milestone-and-platform story to clinical-asset story; a disappointing readout pushes Compugen back to the platform-and-partnership thesis where the multi-year value depends on signing the next BMS-class partnership.